Page 153 - Read Online

Banini et al. Hepatoma Res 2019;5:34 I http://dx.doi.org/10.20517/2394-5079.2019.30 Page 9 of 10

25. Ge W, Yu DC, Li QG, Chen X, Zhang CY, et al. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular
carcinoma and their clinical significances. Clin Lab 2014;60:427-34.
26. El-Abd NE, Fawzy NA, El-Sheikh SM, Soliman ME. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early
detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection. Mol Diagn Ther 2015;19:213-20.
27. Qi P, Cheng SQ, Wang H, Li N, Chen YF, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients
with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.
28. Liu M, Liu J, Wang L, Wu H, Zhou C, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with
transarterial chemoembolization and patient survival. PLoS One 2014;9:e109347.
29. Zekri AN, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, et al. Serum microRNA panels as potential biomarkers for early
detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol 2016;37:12273-86.
30. Mirzaei HR, Sahebkar A, Mohammadi M, Yari R, Salehi H, et al. Circulating microRNAs in hepatocellular carcinoma: potential
diagnostic and prognostic biomarkers. Curr Pharm Des 2016;22:5257-69.
31. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, et al. Noninvasive identification and monitoring of cancer mutations by
targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
32. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, et al. An ultrasensitive method for quantitating circulating tumor DNA with
broad patient coverage. Nat Med 2014;20:548-54.
33. Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B
virus-related hepatocellular carcinoma. Pathology 2012;44:318-24.
34. Huang Z, Hua D, Hu Y, Cheng Z, Zhou X, et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of
hepatocellular carcinoma. Pathol Oncol Res 2012;18:271-6.
35. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number
aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
36. Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma
patients. Proc Natl Acad Sci U S A 2015;112:E1317-25.
37. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular
carcinoma patients. Clin Cancer Res 2000;6:3516-21.
38. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, et al. The prognostic value of circulating plasma DNA level and its allelic imbalance on
chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:399-407.
39. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with
hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006;26:4713-9.
40. Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, et al. Circulating free DNA in the progression of liver damage to
hepatocellular carcinoma. Hepatol Int 2013;7:1050-7.
41. Yan L, Chen Y, Zhou J, Zhao H, Zhang H, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int
J Infect Dis 2018;67:92-7.
42. Szymanska K, Chen JG, Cui Y, Gong YY, Turner PC, et al. TP53 R249S mutations, exposure to aflatoxin, and occurrence of
hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev
2009;18:1638-43.
43. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med 2014;6:224ra24.
44. Yu L, Liu X, Han C, Lu S, Zhu G, et al. XRCC1 rs25487 genetic variant and TP53 mutation at codon 249 predict clinical outcomes of
hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a cohort study for 10 years’ follow up. Hepatol Res 2016;46:765-74.
45. Cai ZX, Chen G, Zeng YY, Dong XQ, Lin MJ, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease
progression in advanced hepatocellular carcinoma. Int J Cancer 2017;141:977-85.
46. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using
droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 2016;7:1907-14.
47. Nault JC, Zucman-Rossi J. Genetics of hepatocellular carcinoma: the next generation. J Hepatol 2014;60:224-6.
48. Kan Z, Zheng H, Liu X, Li S, Barber TD, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Genome Res 2013;23:1422-33.
49. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-4.
50. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic
mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2218.
51. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, et al. Telomerase reverse transcriptase promoter mutation is an
early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology
2014;60:1983-92.
52. Pinyol R, Tovar V, Llovet JM. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. J Hepatol 2014;61:685-7.
53. Hann HW, Jain S, Park G, Steffen JD, Song W, et al. Detection of urine DNA markers for monitoring recurrent hepatocellular
carcinoma. Hepatoma Res 2017;3:105-11.
54. Hosny G, Farahat N, Tayel H, Hainaut P. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with
hepatocellular carcinoma versus chronic liver diseases. Cancer Lett 2008;264:201-8.